GlassScriptPhysician profile
Regina Wiley
NPI 1306384250
$2,173.73
in general payments reported to CMS, 2019-2025
25 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $194 · 2023: $858 · 2024: $444 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $638.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $255.98 | 2023-2025 | |
| Abbvie INC. | $181.88 | 2021-2025 | |
| Lilly USA, LLC | $156.03 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $147.67 | 2021-2024 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $102.06 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $82.84 | 2023-2024 | |
| Corcept Therapeutics | $78.70 | 2023-2025 | Korlym |
| Exact Sciences Corporation | $60.26 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $54.76 | 2023-2024 | Trintellix |
| Shield Therapeutics INC | $47.53 | 2025 | |
| Antares Pharma, INC. | $45.20 | 2024-2025 | Xyosted |
| Biohaven Pharmaceuticals, INC. | $40.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.27 | 2021-2024 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $27.58 | 2023 | |
| Halozyme INC | $26.83 | 2023 | |
| Ironwood Pharmaceuticals, INC | $23.47 | 2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.25 | 2023 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $19.28 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $18.82 | 2024 | Quviviq |
| Hologic Sales and Service, LLC | $18.80 | 2023 | Aptima |
| Esperion Therapeutics, INC. | $15.96 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $15.88 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.